FDA Panel Recommends Novavax COVID Vaccine Despite Heart Inflammation Concerns

(Source: Children’s Health Defense)

The two-dose Novavax COVID-19 vaccine Tuesday came one step closer to obtaining Emergency Use Authorization (EUA) after advisors to the U.S. Food and Drug Administration (FDA) recommended its use in the U.S.

Members of the Vaccines and Related Biological Products Advisory Committee during a public meeting voted 21-0 with one abstention to recommend the vaccine, which is produced by Gaithersburg, Maryland-based Novavax.

The head of the FDA must agree with the advisory panel that the benefits of the Novavax vaccine outweigh its risks before the agency grants the authorization.

While the FDA usually follows the recommendations of its committees, it is not obligated to do so, CNBC reported.